Track market-moving stories before they get noisy

  Toronto, Ontario, August 31, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced continued advancement in participant enrollment for its clinical trial assessing its innovative SCI-210 treatment for symptoms associated with autism spectrum disorder (“ASD”).

  The clinical trial, conducted at Soroka Medical Center in Israel, is a double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of SCI-210 in children diagnosed with ASD. To date, 26 children have been enrolled, marking strong progress toward the planned total of 60 children between the ages of five and 18, each of whom will receive treatment over a 20-week period.

  SCI-210 is an innovative proprietary combination of cannabidiol (“CBD”) and CannAmide™, the Company’s Palmitoylethanolamide-based proprietary formulation. The treatment is being assessed for its ability to alleviate symptoms associated with ASD and to determine whether the dual‑compound approach offers advantages beyond CBD monotherapy.

  The study is designed to evaluate the efficacy and safety of SCI-210 compared with CBD monotherapy. The trial’s primary efficacy endpoints include the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire, the Clinical Global Impressions-Improvement (CGI-I) assessment conducted by a clinician, and determination of the optimal therapeutic dose.

  The ongoing clinical trial is a key element of NeuroThera’s program for SCI-210 and reflects the Company’s broader commitment to advancing innovative treatments for neurological and neurodevelopmental conditions. The study was designed in collaboration with the National Autism Research Center, a leading authority on autism research in Israel.

  Subject to the successful completion of the clinical development program and receipt of applicable regulatory approvals, the Company intends to pursue the commercialization of SCI-210, initially in Israel and subsequently in additional markets.

  About NeuroThera Labs Inc.

NeuroThera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

For further information, please contact:

Michal Efraty

IR Manager

NeuroThera Labs Inc.

Telephone: +972-3-7617108

Email: [email protected]

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Notice on Forward-Looking Statements

This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Forward-looking information can often be identified by words such as "may," "potential," "could," "expects," "anticipates," "intends," "believes" and similar expressions.

Forward-looking information in this news release includes, without limitation, statements regarding: the continued progress and timing of participant enrollment in the Company's clinical trial of SCI-210, including the Company's ability to enroll the planned total of 60 children; the design, conduct, duration and completion of the clinical trial, including the 20-week treatment period; the potential of SCI-210 to alleviate symptoms associated with autism spectrum disorder; whether the combination of CBD and CannAmide™ offers advantages over CBD monotherapy; the ability of the trial to demonstrate the efficacy and safety of SCI-210, to meet its primary efficacy endpoints and to determine an optimal therapeutic dose; the Company's broader development plans for SCI-210 and other treatments for neurological and neurodevelopmental conditions; and the Company's intention to pursue regulatory approval and commercialization of SCI-210, initially in Israel and subsequently in additional markets.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Such factors include, without limitation: the risk that enrollment in the clinical trial will be slower than anticipated, will not reach the planned number of participants, or that participants will withdraw prior to completion; the risk that the clinical trial will be delayed, suspended or terminated for safety, regulatory, operational or other reasons; the risk that SCI-210 will not demonstrate efficacy or safety in the trial, will not meet its primary endpoints, or will not demonstrate an advantage over CBD monotherapy; the inherent uncertainty of pediatric clinical trials in autism spectrum disorder, including reliance on parent-reported and clinician-assessed outcome measures and the potential for a significant placebo response; the risk that an optimal therapeutic dose will not be identified; the risk that results from this trial will not be predictive of results in later-stage or larger trials, or will not support regulatory approval; the Company's reliance on Soroka Medical Center, the National Autism Research Center and other third parties for the conduct of the trial, manufacturing of clinical supply and related activities; the risk that regulatory approvals required to commercialize SCI-210 in Israel or any other jurisdiction will not be obtained on a timely basis, or at all, including uncertainty regarding the regulatory treatment of cannabinoid-based products; the Company's ability to obtain, maintain and enforce intellectual property protection for SCI-210 and CannAmide™; the Company's need for additional financing to complete the clinical development program and the risk that such financing will not be available on acceptable terms, or at all; competition from other companies developing treatments for autism spectrum disorder, some of which have substantially greater resources or are at more advanced stages of development; geopolitical, security and other conditions in Israel, where the clinical trial is being conducted; the Company's status as a subsidiary of SciSparc Ltd. and the potential for conflicts of interest or changes in SciSparc's strategy or ownership; and general economic, market and business conditions, and the risks described in the Company's continuous disclosure documents filed on SEDAR+ (www.sedarplus.ca).

Readers are cautioned that the foregoing list of factors is not exhaustive. These statements are not guarantees of future performance and undue reliance should not be placed on them. The Company does not undertake any obligation to update or revise any forward-looking information, except as required by applicable securities laws.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended June 30, 2026, as well as key recent corporate and clinical developments for Multikine.

Baillie Gifford (Trades, Portfolio), the century-old investment management partnership, executed a significant reduction in its holdings of Service Corp Interna

, /PRNewswire/ -- Service Corporation International (NYSE: SCI), the largest provider of deathcare products and services in North America, today announced that its Board of Directors has approved a quarterly cash dividend of thirty-six cents per share of common stock. The quarterly cash dividend announced today is payable on September 30, 2026 to shareholders of record at the close of business on September 15, 2026. While the Company intends to pay regular quarterly cash dividends for the foreseeable future, all subsequent dividends, and the establishment of record and payment dates, are subject to final determination by the Board of Directors each quarter after its review of the Company's financial performance.

Cautionary Statement on Forward-Looking Statements
The statements in this press release that are not historical facts are forward-looking statements. These forward-looking statements have been made in reliance on the "safe harbor" protections provided under the Private Securities Litigation Reform Act of 1995. These statements may be accompanied by words such as "believe," "estimate," "project," "expect," "anticipate," or "predict," that convey the uncertainty of future events or outcomes. These statements are based on assumptions that we believe are reasonable; however, many important factors could cause our actual results in the future to differ materially from the forward-looking statements made herein and in any other documents or oral presentations made by, or on behalf of us. There can be no assurance that future dividends will be declared. The actual declaration of future dividends, and the establishment of record and payment dates, is subject to final determination by our Board of Directors each quarter after its review of our financial performance. Important factors which could cause actual results to differ materially from those in forward-looking statements include, among others, restrictions on the payment of dividends under existing or future credit agreements or other financing arrangements; changes in tax laws relating to corporate dividends; a determination by the Board of Directors that the declaration of a dividend is not in the best interests of the Company and its shareholders; an increase in our cash needs or a decrease in available cash; or a deterioration in our financial condition or results. For further information on these and other risks and uncertainties, see our Securities and Exchange Commission filings, including our 2025 Annual Report on Form 10-K. Copies of this document as well as other SEC filings can be obtained from our website at http://www.sci-corp.com. We assume no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by us, whether as a result of new information, future events or otherwise.

About Service Corporation International

Service Corporation International (NYSE: SCI), headquartered in Houston, Texas, is North America's leading provider of funeral, cemetery and cremation services, as well as final-arrangement planning in advance, serving approximately 700,000 combined preneed and atneed families each year. Our diversified portfolio of brands provides families and individuals a full range of choices to meet their needs, from simple cremations to full life celebrations and personalized remembrances. Our Dignity Memorial® brand is the name families turn to for professionalism, compassion, and attention to detail that is second to none. At June 30, 2026, we owned and operated 1,495 funeral service locations and 505 cemeteries (of which 316 are combination locations) in 44 states, eight Canadian provinces, the District of Columbia, and Puerto Rico. For more information about Service Corporation International, please visit our website at www.sci-corp.com. For more information about Dignity Memorial®, please visit www.dignitymemorial.com.

For additional information contact:

Investors:

Trey Bocage – Assistant Vice President, Treasury and Investor Relations

(713) 525-3454

Andrea Low – Director, Federal Tax and Investor Relations

(713) 525-2811

Media:

Jay Andrew – Assistant Vice President, Corporate Communications

(713) 525-3468

SOURCE Service Corporation International

Service Corporation International (SCI) Q2 2026 Earnings Call Transcript

Thursday, 30 July 2026 08:30 AM

Topic: 

Earnings COLUMBUS, OH / ACCESS Newswire / July 30, 2026 / SCI Engineered Materials, Inc. ("SCI" or "Company") (OTCQB:SCIA), today reported financial results for the three months and six months ended July 30, 2026.

Jeremy Young, President and Chief Executive Officer, commented, "SCI's second quarter results reflect solid achievements throughout the Company. Revenue increased significantly compared to a year ago due to higher raw material input costs, favorable product mix and increased volume. We are gaining traction in key markets consistent with our growth strategy through expanded marketing initiatives, increased demand for SCI's products and services, and the addition of new customers."

Mr. Young added, "We recently ordered manufacturing equipment and added staff to enhance future growth. In addition to increased product sales, interest in SCI's breadth of services to fulfill specific customer needs is growing, including debinding capabilities for commercial additive manufacturing applications and specialty diffusion bonding. Customer emphasis on domestic manufacturing is increasing as they seek to prioritize their sourcing requirements with price sensitivity."

Revenue

Revenue increased 163% to a record $9,485,119 for the three months ended June 30, 2026, versus $3,609,304 for the same period last year. The year-over-year increase was due to higher raw material input costs, product mix and higher volume.

For the first six months of 2026, revenue increased 148% to $17,645,481 from $7,109,536 a year ago, led by product mix, higher raw material input costs and volume.

Order backlog was $7.9 million at June 30, 2026, versus $7.1 million at March 31, 2026, and $3.4 million at June 30, 2025.

Gross profit

Gross profit increased 97% to $2,276,455 for the second quarter of 2026 versus $1,158,157 a year ago, due to the increase in revenue. The Company's gross profit margin declined to 24.0% from 32.1% last year principally due to higher raw material input costs and product mix.

Gross profit for the first six months of 2026 increased 93% to $4,311,575 from $2,230,971 last year due to the increase in revenue. The gross profit margin declined to 24.4% from 31.4% for the same period a year ago reflecting higher raw material input costs and product mix compared to the same period in 2025.

Operating expenses

Operating expenses increased 9% to $876,989 for the three months ended June 30, 2026, versus $802,350 a year ago. The year-over-year increase was primarily due to higher compensation and benefits for Marketing and Sales, including additional staff, and higher Research and Development materials and supplies, partially offset by lower General and Administrative expense.

Operating expenses for the first six months of 2026 were $2,423,185, including fraud expense of $562,026, compared to $1,572,625 for the same period last year. Key factors in the year-over-year comparison include the 2026 first quarter fraud expense, higher Marketing and Sales compensation and benefits expense, including increased staff, additional materials and supplies for Research and Development, and slightly higher General and Administrative compensation and benefits versus the first six months of 2025.

Fraud expense

On February 10, 2026, the Company reported it was subjected to an imposter scam of $898,325 executed in conjunction with bank fraud. As of June 30, 2026, the Company recovered $336,299 of that amount resulting in fraud expense of $562,026 recorded in the first quarter. On July 12, 2026, the Company was informed that a $250,000 claim related to its Smart Cyber insurance policy was approved. When the insurance proceeds are realized they will reduce the fraud expense to $312,026.

Net interest income

Net interest income was $110,359 for the second quarter of 2026 versus $115,680 the prior year primarily due to lower interest rates compared to the same period a year ago. For the first half of 2026, net interest income was $219,445 compared to $213,810 last year primarily due to an increase in cash and cash equivalents since 2025 year-end.

Income taxes

The Company's income tax expense increased 217% to $339,549 for the three months ended June 30, 2026, from $107,028 last year due to higher taxable income. Income tax expense for the first half of 2026 was $475,297 versus $197,980 a year ago, an increase of 140%. The Company's effective tax rate for the second quarter and first half of 2026 was 22.5% compared to 22.7% for the same periods in 2025. The deferred tax liability was $763,983 at June 30, 2026, versus $389,572 at December 31, 2025.

Net income

Net income increased 221% to $1,170,276 for the second quarter of 2026 compared to $364,459 a year ago due to higher gross profit. Net income per share was $0.26 for the three months ended June 30, 2026, versus $0.08 for the same period a year ago.

For the first half of 2026, net income increased 142% to $1,632,538 from $674,176 for the first half of 2025. Net income per share was $0.37 for the six months ended June 30, 2026, versus $0.15 a year ago. Weighted average shares outstanding were approximately 3% below the comparable three- and six-month periods in 2025 due to the Company's share repurchase program initiated on December 1, 2025.

Cash and cash equivalents and Investments in marketable securities

Cash and cash equivalents were $9,889,753 at June 30, 2026, compared to $7,939,000 at December 31, 2025, an increase of approximately 25%. Investments in marketable securities totaled $3,368,250 at June 30, 2026, compared to $3,367,125 at December 31, 2025.

About SCI Engineered Materials, Inc.

SCI Engineered Materials is a global supplier and manufacturer of advanced materials for PVD thin film applications and works closely with end users and OEMs to develop innovative, customized solutions. Additional information is available at www.sciengineeredmaterials.com or follow SCI Engineered Materials, Inc. at:

https://www.linkedin.com/company/sci-engineered-materials.-inc
https://www.facebook.com/sciengineeredmaterials/
https://x.com/SciMaterials

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Those statements include, but are not limited to, all statements regarding intent, beliefs, expectations, projections, customer guidance, forecasts, plans of the Company and its management. These forward-looking statements involve numerous risks and uncertainties, including without limitation, other risks and uncertainties detailed from time to time in the Company's Securities and Exchange Commission filings, including the Company's Annual Report on Form 10-K for the year ended December 31, 2025. One or more of these factors has affected and could affect the Company's projections in the future. Therefore, there can be no assurances that the forward-looking statements included in this press release will prove to be accurate. Due to the significant uncertainties in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company, or any other persons, that the objectives and plans of the Company will be achieved. All forward-looking statements made in this press release are based on information presently available to the management of the Company. The Company assumes no obligation to update any forward-looking statements.

Contact: Robert Lentz
(614) 439-6006

SCI ENGINEERED MATERIALS, INC.
CONDENSED BALANCE SHEETS

ASSETS

June 30,

December 31,

2026

2025

(UNAUDITED)

Current Assets

Cash and cash equivalents

$

9,889,753

$

7,939,000

Investments - marketable securities, short term

799,250

298,125

Accounts receivable, less allowance for doubtful accounts

1,041,650

720,364

Inventories

3,624,420

1,091,471

Prepaid purchase orders and expenses

379,820

196,491

Total current assets

15,734,893

10,245,451

Property and Equipment, at cost

11,491,339

10,854,986

Less accumulated depreciation and amortization

(8,018,015

)

(8,020,249

)

Property and equipment, net

3,473,324

2,834,737

Investments, net - marketable securities, long term

2,569,000

3,069,000

Right of use asset, net

959,224

1,061,709

Other assets

58,993

61,461

Total other assets

3,587,217

4,192,170

TOTAL ASSETS

$

22,795,434

$

17,272,358

LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities

Operating lease, short term

$

232,011

$

212,561

Accounts payable

477,280

245,523

Customer deposits

4,546,123

829,158

Accrued expenses

418,765

568,503

Total current liabilities

5,674,179

1,855,745

Deferred tax liability

763,983

389,572

Operating lease, long term

727,212

849,148

Total liabilities

7,165,374

3,094,465

Total shareholders' equity

15,630,060

14,177,893

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

$

22,795,434

$

17,272,358

SCI ENGINEERED MATERIALS, INC
STATEMENTS OF INCOME
(UNAUDITED)

THREE MONTHS ENDED JUNE 30,

SIX MONTHS ENDED JUNE 30,

2026

2025

2026

2025

Revenue

$

9,485,119

$

3,609,304

$

17,645,481

$

7,109,536

Cost of revenue

7,208,664

2,451,147

13,333,906

4,878,565

Gross profit

2,276,455

1,158,157

4,311,575

2,230,971

General and administrative expense

512,090

549,540

1,154,133

1,097,361

Fraud expense

-

-

562,026

-

Research and development expense

147,433

107,374

290,043

209,641

Marketing and sales expense

217,466

145,436

416,983

265,623

Income from operations

1,399,466

355,807

1,888,390

658,346

Interest income, net

110,359

115,680

219,445

213,810

Income before provision for income taxes

1,509,825

471,487

2,107,835

872,156

Income tax expense

339,549

107,028

475,297

197,980

NET INCOME

$

1,170,276

$

364,459

$

1,632,538

$

674,176

Earnings per share - basic and diluted

Income per common share

Basic

$

0.26

$

0.08

$

0.37

$

0.15

Diluted

$

0.26

$

0.08

$

0.37

$

0.15

Weighted average shares outstanding

Basic

4,450,003

4,574,686

4,460,059

4,571,425

Diluted

4,450,003

4,578,926

4,460,059

4,575,729

SCI ENGINEERED MATERIALS, INC
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)

SIX MONTHS ENDED JUNE 30,

2026

2025

CASH PROVIDED BY (USED IN):

Operating activities

$

3,088,988

$

1,923,241

Investing activities

(870,735

)

(705,976

)

Financing activities

(267,500

)

-

NET INCREASE IN CASH

1,950,753

1,217,265

CASH - Beginning of period

7,939,000

6,753,403

CASH - End of period

$

9,889,753

$

7,970,668

SOURCE: SCI Engineered Materials, Inc.

Service Corp. (SCI - Free Report) reported $1.1 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 3.6%. EPS of $0.90 for the same period compares to $0.88 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $1.08 billion, representing a surprise of +2.04%. The company delivered an EPS surprise of +1.12%, with the consensus EPS estimate being $0.89.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Service Corp. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Total comparable funeral average revenue per service: $6,016.00 compared to the $6,011.61 average estimate based on two analysts.Funeral services performed: 87,347 versus 85,320 estimated by two analysts on average.Revenue- Funeral: $604.8 million versus $594.3 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +2.3% change.Revenue- Cemetery: $498.5 million versus the three-analyst average estimate of $486.93 million. The reported number represents a year-over-year change of +5.2%.Revenue- Cemetery- Core: $452.3 million compared to the $447.25 million average estimate based on two analysts. The reported number represents a change of +3.5% year over year.Revenues - Cemetery - Total recognized preneed revenue: $341.6 million versus the two-analyst average estimate of $337.91 million.Revenue- Cemetery- Core- Atneed: $110.7 million versus the two-analyst average estimate of $109.34 million. The reported number represents a year-over-year change of -0.3%.Revenue- Funeral- Core general agency and other: $60.1 million compared to the $58.66 million average estimate based on two analysts. The reported number represents a change of +0.7% year over year.Revenue- Funeral- Non-funeral home preneed sales: $21.2 million versus the two-analyst average estimate of $26.34 million. The reported number represents a year-over-year change of -19.7%.Revenue- Cemetery- Other: $46.2 million versus the two-analyst average estimate of $39.76 million. The reported number represents a year-over-year change of +25.2%.Gross profit- Funeral: $110.3 million compared to the $107.78 million average estimate based on three analysts.Gross profit- Cemetery: $163.2 million compared to the $163.77 million average estimate based on three analysts.View all Key Company Metrics for Service Corp. here>>>

Shares of Service Corp. have returned +11.9% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Conference call on Thursday, July 30, 2026, at 8:00 a.m. Central Time. 

, /PRNewswire/ -- Service Corporation International (NYSE: SCI), the largest provider of deathcare products and services in North America, today reported results for the second quarter of 2026.

Second Quarter Highlights:

Consolidated revenue grew $37.8 million, or 4%, over the second quarter of 2025 Comparable total funeral sales average grew 3% over the second quarter of 2025 Comparable cemetery preneed sales production increased 8% in the current quarter Comparable funeral preneed sales production increased 7% in the current quarter GAAP earnings per share was $0.90 compared to $0.86 in the second quarter of 2025 Adjusted earnings per share was $0.90 compared to $0.88 in the second quarter of 2025 Net cash provided by operating activities increased $72.2 million, or 43%, to $238.7 million in the current quarter compared to $166.5 million in the prior-year quarter Adjusted cash provided by operating activities increased $70.5 million, or 42%, to $238.8 million in the current quarter compared to $168.3 million in the prior year Tom Ryan, the Company's Chairman and CEO, commented on the second quarter performance:

"Today, we reported adjusted earnings per share of $0.90 and adjusted net cash provided by operating activities of $238.8 million, both ahead of the prior year and our expectations. Our funeral segment benefited from a continued strong average revenue per service which more than offset a better-than-expected 1% decline in funeral services performed. Our cemetery segment continued to perform well, generating 5% growth in comparable cemetery revenue. The growth was primarily driven by higher recognized preneed merchandise and service revenue, as well as higher other revenue, both of which reflected impressive earnings growth from our cemetery trust funds. Additionally, recognized preneed property revenue grew 2%, while preneed property production grew 7%. This dynamic puts temporary pressure on cemetery gross margins but expands our backlog with higher-margin deferred property sales, which will benefit us in future periods. Preneed funeral sales production also remained strong, increasing 7% on a comparable basis, reinforcing the long-term strength of our preneed strategy and helping to build our backlog of future revenue.

We remain focused on executing our long-term growth strategy by growing revenue, leveraging our scale, and allocating capital in a disciplined manner to create long-term shareholder value. Our consistent cash generation continues to provide the financial flexibility to invest in strategic acquisitions, expand and develop our cemetery portfolio, pursue attractive real estate opportunities, and construct new funeral homes. Thus far this year, we returned $363 million to shareholders through dividends and share repurchases, reflecting our continued commitment to balanced capital allocation. This balanced capital allocation strategy positions us to deliver sustainable growth and create long-term shareholder value.

Finally, I would like to thank our more than 25,000 associates for their unwavering commitment to serving client families with compassion, professionalism, and excellence. Their dedication is the foundation of our success and continues to distinguish SCI every day."

Details of our second quarter 2026 financial results and the unaudited consolidated financial statements can be found in the Appendix at the end of this press release. The table below summarizes our key financial results.

(Dollars in millions, except for per share amounts)

Three months ended June 30,

Six months ended June 30,

2026

2025

2026

2025

Revenue

$      1,103.3

$      1,065.4

$      2,199.7

$      2,139.6

Operating income

$         231.6

$         224.5

$         475.4

$         476.1

Net income attributable to common stockholders

$         124.8

$         122.9

$         260.6

$         265.7

Diluted earnings per share

$          0.90

$          0.86

$          1.87

$          1.84

Earnings excluding special items (1)

$         124.9

$         125.5

$         260.1

$         265.1

Diluted earnings per share excluding special items (1)

$          0.90

$          0.88

$          1.87

$          1.84

Diluted weighted average shares outstanding

138.3

143.0

139.1

144.1

Net cash provided by operating activities

$         238.7

$         166.5

$         572.4

$         477.6

Net cash provided by operating activities excluding
special items (1)

$         238.8

$         168.3

$         573.3

$         484.2

(1)

Earnings excluding special items, diluted earnings per share excluding special items, and net cash provided by operating activities excluding special items are non-GAAP financial measures. These items are also referred to as "adjusted earnings per share" and "adjusted operating cash flow". A reconciliation from net income attributable to common stockholders, diluted earnings per share, and net cash provided by operating activities in accordance with generally accepted accounting principles in the United States (GAAP) can be found under the headings "Cash Flow and Capital Spending" and "Non-GAAP Financial Measures" in the Appendix at the end of this press release.

Diluted earnings per share was $0.90 in the second quarter of 2026 compared to $0.86 in the second quarter of 2025. The current year quarter was impacted by $0.1 million of net losses on divestitures and impairment charges compared to $4.1 million of net gains in the prior year. The prior year also included a $6.4 million charge related to the settlement of certain legal matters and a $1.6 million restructuring charge. Diluted earnings per share, excluding special items, was $0.90 in the second quarter of 2026 compared to $0.88 in the second quarter of 2025. Higher cemetery gross profit combined with a lower share count more than offset lower funeral gross profit. Net cash provided by operating activities increased $72.2 million, or 43%, to $238.7 million in the second quarter of 2026. Adjusted cash provided by operating activities increased $70.5 million, or 42%, to $238.8 million in the current quarter compared to $168.3 million in the prior year primarily due to a reduction in cash taxes and strong operating cash receipts from increased preneed cemetery sales production. CONFIRMED 2026 EPS GUIDANCE AND RAISED 2026 CASH FLOW GUIDANCE

The $4.20 midpoint of our annual guidance range for 2026 detailed below is confirmed with a more narrow range expected for adjusted earnings per share of $4.10 to $4.30. Our cash flow outlook at the midpoint has increased $50 million from $1,035 million to $1,085 million due to stronger cemetery preneed cash receipts. Additionally, we increased our total maintenance capital expenditures by $10 million to $335 million. Our outlook for diluted earnings per share from continuing operations excluding special items, at the midpoint of our guidance range, is anticipated to be within our expected long-term growth framework of 8%-12%.

(Dollars in millions, except per share amounts)

2026 Outlook

Revised 2026 Outlook

Diluted earnings per share excluding special items (1)

$4.05 - $4.35

$4.10 - $4.30

Net cash provided by operating activities excluding special items and cash
taxes (1)

$1,125 - $1,185

$1,175 - $1,235

Cash taxes expected in 2026 (at the midpoint of diluted earnings per share
excluding special items guidance)

$120

$120

Net cash provided by operating activities excluding special items (1)

$1,005 - $1,065

$1,055 - $1,115

Midpoint of net cash provided by operating activities excluding special items (1)

$1,035

$1,085

Capital improvements at existing field locations

$135

$140

Development of cemetery property

$165

$170

Digital investments and corporate

$25

$25

Total maintenance, cemetery development, and other capital expenditures
(Maintenance capital expenditures)

$325

$335

(1)

Diluted earnings per share excluding special items, net cash provided by operating activities excluding special items and cash taxes, and net cash provided by operating activities excluding special items are non-GAAP financial measures. We normally reconcile these non-GAAP financial measures from diluted earnings per share and net cash provided by operating activities; however, diluted earnings per share and net cash provided by operating activities calculated in accordance with GAAP are not currently accessible on a forward-looking basis. Our outlook for 2026 excludes the following because this information is not currently available for 2026: Expenses net of insurance recoveries related to hurricanes, gains or losses associated with asset divestitures, gains or losses associated with the early extinguishment of debt, potential tax reserve adjustments and IRS payments and/or refunds, acquisition and integration costs, system implementation and transition costs, and potential costs associated with estimated litigation charges or legal settlements or the recognition of receivables for insurance recoveries associated with litigation, or deferred tax payments. The foregoing items could materially impact our forward-looking diluted earnings per share and/or our net cash provided by operating activities calculated in accordance with GAAP, consistent with the historical disclosures found in the Appendix at the end of this press release under the headings "Cash Flow and Capital Spending" and "Non-GAAP Financial Measures".

CONFERENCE CALL AND WEBCAST

We will host a conference call on Thursday, July 30, 2026, at 8:00 a.m. Central Time. A question and answer session will follow prepared remarks made by management. The conference call dial-in numbers are (888) 317-6003 (US) or (412) 317-6061 (International) with the passcode of 7565620. The conference call will also be broadcast live via the Internet and can be accessed through our website at www.sci-corp.com. A replay of the conference call will be available through August 6, 2026 and can be accessed at (855) 669-9658 (US) or (412) 317-0088 (International) with the passcode of 1797873. Additionally, a replay of the conference call will be available on our website for approximately three months.

ABOUT SERVICE CORPORATION INTERNATIONAL

Service Corporation International (NYSE: SCI), headquartered in Houston, Texas, is North America's leading provider of funeral, cemetery and cremation services, as well as final-arrangement planning in advance, serving approximately 700,000 combined preneed and atneed families each year. Our diversified portfolio of brands provides families and individuals a full range of choices to meet their needs, from simple cremations to full life celebrations and personalized remembrances. Our Dignity Memorial® brand is the name families turn to for professionalism, compassion, and attention to detail that is second to none. At June 30, 2026, we owned and operated 1,495 funeral service locations and 505 cemeteries (of which 316 are combination locations) in 44 states, eight Canadian provinces, the District of Columbia, and Puerto Rico. For more information about Service Corporation International, please visit our website at www.sci-corp.com. For more information about Dignity Memorial®, please visit www.dignitymemorial.com. 

For additional information contact: [email protected]

Investors:

Trey Bocage - Assistant Vice President - Treasury and Investor Relations

(713) 525-3454

Andrea Low - Director - Federal Tax and Investor Relations

(713) 525-2811

Media:

Jay Andrew - Assistant Vice President - Corporate Communications

(713) 525-3468

CAUTIONARY STATEMENT ON FORWARD-LOOKING STATEMENTS

The statements in this press release that are not historical facts are forward-looking statements made in reliance on the safe harbor protections provided under the Private Securities Litigation Reform Act of 1995. These statements may be accompanied by words such as "believe", "estimate", "project", "expect", or "anticipate", "predict" that convey the uncertainty of future events or outcomes. These statements are based on assumptions that we believe are reasonable; however, many important factors could cause our actual results in the future to differ materially from the forward-looking statements made herein and in any other documents or oral presentations made by, or on behalf of, the Company. These factors are discussed below. Except as required by applicable law, we assume no obligation and make no undertaking to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company, whether as a result of new information, future events, or otherwise.

Our affiliated trust funds own investments in securities, which are affected by market conditions that are beyond our control. We may be required to replenish our affiliated funeral and cemetery trust funds to meet minimum funding requirements, which would have a negative effect on our earnings and cash flow. Our ability to execute our strategic plan depends on many factors, some of which are beyond our control. We may be adversely affected by the effects of inflation. Our results may be adversely affected by significant weather events, natural disasters, catastrophic events, or public health crises. Our credit agreements contain covenants that may prevent us from engaging in certain transactions. If we lost the ability to use surety bonding to support our preneed activities, we may be required to make material cash payments to fund certain trust funds. The financial condition of third-party insurance companies that fund our preneed contracts may impact our future revenue. Unfavorable publicity could affect our reputation and business. Our failure to attract and retain qualified sales personnel and licensed funeral professionals could have an adverse effect on our business and financial condition. We use a combination of insurance, self-insurance, and large deductibles in managing our exposure to certain inherent risks; therefore, we could be exposed to unexpected costs that could negatively affect our financial performance. Declines in overall economic conditions beyond our control could reduce future potential earnings and cash flows and could result in future impairments to goodwill and/or other intangible assets. Any failure to protect personal information relating to our customers, their loved ones, our associates, and our vendors could damage our reputation, could cause us to incur substantial additional costs and to become subject to litigation, and could adversely affect our operating results, financial condition, or cash flow. A failure of a key information technology system or process could disrupt and adversely affect our business. Our Canadian business exposes us to operational, economic, and currency risks. Our level of indebtedness could adversely affect our cash flows, our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or our industry, and may prevent us from fulfilling our obligations under our indebtedness. The funeral and cemetery industry is competitive. If the number of deaths in our markets declines, our cash flows and revenue may decrease. Changes in the number of deaths are not predictable from market to market or over the short term. If we are not able to respond effectively to changing consumer preferences, our market share, revenue, and/or profitability could decrease. The continuing upward trend in life expectancy and an increase in the number of cremations performed in North America could result in lower revenue, operating profit, and cash flows. Our funeral and cemetery businesses are high fixed-cost businesses. Risks associated with our supply chain, such as tariffs, could materially adversely affect our financial performance. Regulation and compliance could have a material adverse impact on our financial results. Unfavorable results of litigation could have a material adverse impact on our financial statements. Cemetery burial practice claims could have a material adverse impact on our financial results. The application of unclaimed property laws by certain states to our preneed funeral and cemetery backlog could have a material adverse impact on our liquidity, cash flows, and financial results. Changes in taxation, or the interpretation of tax laws or regulations, as well as the inherent difficulty in quantifying potential tax effects of business decisions could have a material adverse effect on the results of our operations, financial condition, or cash flows. For further information on these and other risks and uncertainties, see our Securities and Exchange Commission filings, including our 2025 Annual Report on Form 10-K. Copies of this document as well as other SEC filings can be obtained from our website at www.sci-corp.com. 

SERVICE CORPORATION INTERNATIONAL

APPENDIX: RESULTS FOR THE SECOND QUARTER OF 2026

Consolidated Statement of Operations (Unaudited)

(Dollars in thousands, except per share amounts)

Three Months Ended

Six Months Ended

June 30,

June 30,

2026

2025

2026

2025

Revenue

$   1,103,288

$   1,065,444

$   2,199,742

$   2,139,611

Cost of revenue

(829,787)

(794,006)

(1,639,790)

(1,576,756)

Gross profit

273,501

271,438

559,952

562,855

Corporate general and administrative expenses

(41,775)

(49,466)

(85,686)

(94,167)

Restructuring charge

—

(1,575)

—

(1,575)

(Losses) gains on divestitures and impairment charges, net

(138)

4,062

1,136

9,033

Operating income

231,588

224,459

475,402

476,146

Interest expense

(64,711)

(64,071)

(128,717)

(125,554)

Other (expense) income, net

(57)

3,914

1,341

7,066

Income before income taxes

166,820

164,302

348,026

357,658

Provision for income taxes

(41,943)

(41,378)

(87,276)

(91,807)

Net income

124,877

122,924

260,750

265,851

Net income attributable to noncontrolling interests

(52)

(59)

(117)

(106)

Net income attributable to common stockholders

$     124,825

$     122,865

$     260,633

$     265,745

Basic earnings per share:

Net income attributable to common stockholders

$          0.91

$          0.87

$          1.89

$          1.86

Basic weighted average number of shares

137,519

141,897

138,268

143,001

Diluted earnings per share:

Net income attributable to common stockholders

$          0.90

$          0.86

$          1.87

$          1.84

Diluted weighted average number of shares

138,327

142,992

139,122

144,134

Consolidated Balance Sheet (Unaudited)

(Dollars in thousands, except share amounts)

June 30, 2026

December 31,
2025

ASSETS

Current assets:

Cash and cash equivalents

$            260,411

$            243,581

Receivables, net of reserves of $3,602 and $3,944, respectively

104,109

100,415

Inventories

38,235

35,246

Other

46,991

32,551

Total current assets

449,746

411,793

Preneed receivables, net of reserves of $33,925 and $34,680, respectively, and
trust investments

7,652,394

7,360,793

Cemetery property

2,251,528

2,201,967

Property and equipment, net

2,835,540

2,751,761

Goodwill

2,174,837

2,169,055

Deferred charges and other assets, net of reserves of $2,826 and $2,460,
respectively

1,329,669

1,360,530

Cemetery perpetual care trust investments

2,520,779

2,398,613

Total assets

$        19,214,493

$        18,654,512

LIABILITIES & EQUITY

Current liabilities:

Accounts payable and accrued liabilities

$            650,833

$            685,156

Current maturities of long-term debt

195,149

56,847

Income taxes payable

246

3,701

Total current liabilities

846,228

745,704

Long-term debt

5,108,016

5,082,970

Deferred revenue, net

1,823,627

1,779,266

Deferred tax liability

704,103

691,033

Other liabilities

571,893

550,793

Deferred receipts held in trust

6,116,618

5,784,398

Care trusts' corpus

2,506,248

2,381,507

Commitments and contingencies

Equity:

Common stock, $1 per share par value, 500,000,000 shares authorized,
142,249,152 and 141,957,004 shares issued, respectively, and 136,619,474 and
139,678,199 shares outstanding, respectively

136,619

139,678

Capital in excess of par value

976,452

987,210

Retained earnings

427,900

498,958

Accumulated other comprehensive income

(3,720)

12,425

Total common stockholders' equity

1,537,251

1,638,271

Noncontrolling interests

509

570

Total equity

1,537,760

1,638,841

Total liabilities and equity

$        19,214,493

$        18,654,512

Consolidated Statement of Cash Flows (Unaudited)

(Dollars in thousands)

Six months ended June 30,

2026

2025

Cash flows from operating activities:

Net income

$         260,750

$         265,851

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

114,081

108,257

Amortization of intangibles

7,038

8,441

Amortization of cemetery property

48,581

48,195

Amortization of loan costs

4,474

4,383

Provision for expected credit losses

4,217

5,234

Provision for deferred income taxes

13,307

4,621

Gains on divestitures and impairment charges, net

(1,136)

(9,033)

Share-based compensation

10,387

9,589

Change in assets and liabilities, net of effects from acquisitions and divestitures:

(Increase) decrease in receivables

(5,094)

6,205

Decrease (increase) in other assets

24,982

(16,110)

Increase in payables and other liabilities

21,679

11,996

Effect of preneed sales production and maturities:

Decrease (increase) in preneed receivables, net and trust investments

8,318

(28,062)

Increase in deferred revenue, net

40,995

23,785

Increase in deferred receipts held in trust

19,860

34,228

Net cash provided by operating activities

572,439

477,580

Cash flows from investing activities:

Capital expenditures

(175,593)

(161,201)

Business acquisitions, net of cash acquired

(39,469)

(28,242)

Real estate acquisitions

(12,835)

(5,422)

Corporate headquarters

(56,334)

(26,759)

Proceeds from divestitures and sales of property and equipment

5,331

26,762

Payments for Company-owned life insurance policies

(124)

(130)

Proceeds from Company-owned life insurance policies and other

—

3,757

Tax credit equity investments

(40,737)

—

Net cash used in investing activities

(319,761)

(191,235)

Cash flows from financing activities:

Proceeds from issuance of long-term debt

405,000

495,001

Scheduled payments of debt

(13,648)

(12,827)

Early payments of debt

(295,000)

(305,000)

Proceeds from corporate headquarters debt facility

51,854

17,120

Principal payments on finance leases

(19,783)

(18,853)

Proceeds from exercise of stock options

6,599

4,040

Purchase of Company common stock

(266,377)

(324,023)

Payments of dividends

(96,363)

(91,129)

Bank overdrafts and other

(4,773)

(7,354)

Net cash used in financing activities

(232,491)

(243,025)

Effect of foreign currency

(4,938)

5,800

Net increase in cash, cash equivalents, and restricted cash

15,249

49,120

Cash, cash equivalents, and restricted cash at beginning of period

246,468

221,399

Cash, cash equivalents, and restricted cash at end of period

$         261,717

$         270,519

Consolidated Segment Results

(See definitions of revenue line items later in this appendix.)

(Dollars in millions, except funeral services
performed and average revenue per service)

Three months ended

June 30,

Six months ended

June 30,

2026

2025

2026

2025

Consolidated funeral:

Atneed revenue

$      298.7

$      296.1

$      618.9

$      625.2

Matured preneed revenue

196.5

183.5

401.9

389.3

Core revenue

495.2

479.6

1,020.8

1,014.5

Non-funeral home revenue

27.6

25.7

56.4

53.4

Non-funeral home preneed sales revenue

21.3

26.4

43.5

48.6

Core general agency and other revenue

60.7

59.7

114.7

114.4

Total revenue

$      604.8

$      591.4

$    1,235.4

$   1,230.9

Gross profit

$      110.3

$      116.0

$      244.3

$      270.0

Gross profit percentage

18.2 %

19.6 %

19.8 %

21.9 %

Funeral services performed

87,347

87,014

181,033

184,868

Average revenue per service

$      5,985

$      5,807

$      5,950

$      5,777

(Dollars in millions)

Three months ended June
30,

Six months ended June 30,

2026

2025

2026

2025

Consolidated cemetery:

Atneed property revenue

$       37.5

$       37.0

$       74.0

$       74.2

Atneed merchandise and service revenue

73.2

74.0

145.9

149.1

Total atneed revenue

110.7

111.0

219.9

223.3

Recognized preneed property revenue

225.4

220.4

435.0

409.1

Recognized preneed merchandise and service revenue

116.2

105.8

222.5

204.3

Total recognized preneed revenue

341.6

326.2

657.5

613.4

Core revenue

452.3

437.2

877.4

836.7

Other cemetery revenue

46.2

36.9

87.0

72.1

Total revenue

$      498.5

$      474.1

$      964.4

$      908.8

Gross profit

$      163.2

$      155.5

$      315.7

$      292.9

Gross profit percentage

32.7 %

32.8 %

32.7 %

32.2 %

Comparable Funeral Results

The table below details comparable funeral results of operations ("same store") for the three months ended June 30, 2026 and 2025. We consider comparable funeral operations to be those businesses owned for the entire period beginning January 1, 2025 and ending June 30, 2026.

(Dollars in millions, except average revenue per service and
average revenue per contract sold)

Three months ended June 30,

2026

2025

Var

%

Comparable funeral revenue:

Atneed revenue (1)

$  290.2

$  294.3

$   (4.1)

(1.4) %

Matured preneed revenue (2)

194.0

182.8

11.2

6.1 %

Core revenue (3)

484.2

477.1

7.1

1.5 %

Non-funeral home revenue (4)

27.4

25.1

2.3

9.2 %

Non-funeral home preneed sales revenue (5)

21.2

26.3

(5.1)

(19.4) %

Core general agency and other revenue (6)

60.1

59.3

0.8

1.3 %

Total comparable revenue

$  592.9

$  587.8

$     5.1

0.9 %

Comparable gross profit

$  109.8

$  116.6

$   (6.8)

(5.8) %

Comparable gross profit percentage

18.5 %

19.8 %

(1.3) %

Comparable funeral services performed:

Atneed

44,482

45,873

(1,391)

(3.0) %

Matured preneed

26,384

26,247

137

0.5 %

Total core

70,866

72,120

(1,254)

(1.7) %

Non-funeral home

14,178

14,109

69

0.5 %

Total comparable funeral services performed

85,044

86,229

(1,185)

(1.4) %

Core cremation rate

58.0 %

57.4 %

0.6 %

Total comparable cremation rate (7)

64.8 %

64.3 %

0.5 %

Comparable funeral average revenue per service:

Atneed

$  6,524

$  6,416

$    108

1.7 %

Matured preneed

7,353

6,965

388

5.6 %

Total core

6,833

6,615

218

3.3 %

Non-funeral home

1,933

1,779

154

8.7 %

Total comparable average revenue per service

$  6,016

$  5,824

$    192

3.3 %

Comparable funeral preneed sales production:

Total preneed sales

$  323.3

$  303.4

$   19.9

6.6 %

Core contracts sold

38,642

36,232

2,410

6.7 %

Non-funeral home contracts sold

20,420

20,923

(503)

(2.4) %

Core average revenue per contract sold

6,706

6,604

102

1.5 %

Non-funeral home average revenue per contract sold

$  3,141

$  3,068

$      73

2.4 %

(1)

Atneed revenue represents merchandise and services sold and delivered or performed once death has occurred.

(2)

Matured preneed revenue represents merchandise and services sold on a preneed contract through our core funeral homes, which have been delivered or performed as well as the related merchandise and service trust fund income and other insurance benefits.

(3)

Core revenue represents the sum of merchandise and services sold on an atneed contract or preneed contract, which were delivered or performed once death has occurred through our core funeral homes.

(4)

Non-funeral home revenue represents services sold on a preneed or atneed contract through one of our non-funeral home sales channels (e.g. SCI Direct) and performed once death has occurred.

(5)

Non-funeral home preneed sales revenue represents travel protection, net and merchandise sold on a preneed contract that is delivered before death has occurred and general agency revenue from our non-funeral home sales channel.

(6)

Core general agency and other revenue primarily comprises core general agency revenue, which is commissions we receive from third-party insurance companies for life insurance policies sold to preneed customers for the purpose of funding preneed arrangements and core travel protection preneed sales, net.

(7)

Total comparable cremation rate includes the impact of cremation services through our non-funeral sales channel (e.g. SCI Direct).

Total comparable funeral revenue increased $5.1 million. Core funeral revenue increased $7.1 million, or 1.5%, primarily due to a 3.3% increase in core average revenue per service partially offset by a 1.7% decrease in core funeral services performed. The growth in the average revenue per service is primarily driven by consumer preferences for enhanced product and service offerings as well as an increase in trust fund income. The core cremation rate increased 60 basis points to 58.0%. Non-funeral home revenue increased $2.3 million, or 9.2%, due to an 8.7% increase in non-funeral home average revenue per service driven by increased matured preneed revenue from the backlog, combined with a 0.5% increase in non-funeral home services performed. Non-funeral home preneed sales revenue decreased $5.1 million, primarily due to an operational shift to defer the delivery of urns on preneed contracts to the time of need. This transition was completed late in 2025, and this decrease is short-term in nature as we will recognize deferred urn revenue from the backlog at the time of need as non-funeral home revenue in future periods. Core general agency and other revenue increased $0.8 million. Core general agency revenue benefited from higher insurance sales production which was largely offset by a lower general agency commission rate quarter over quarter. The current commission rate is stable and is trending in line with expectations. Comparable funeral gross profit decreased $6.8 million to $109.8 million, and the gross profit percentage declined 130 basis points from 19.8% to 18.5%. Gross profit was impacted by higher selling compensation associated with strong insurance-funded preneed sales production. Selling compensation costs associated with insurance-funded preneed sales production are expensed as incurred, while the benefit of these sales will be realized in future periods as the related funeral services are performed. Comparable funeral preneed sales production increased $19.9 million, or 6.6%, in the second quarter of 2026 compared to 2025, driven by an 8.3% increase in core preneed sales production. Comparable Cemetery Results

The table below details comparable cemetery results of operations ("same store") for the three months ended June 30, 2026 and 2025. We consider comparable cemetery operations to be those businesses owned for the entire period beginning January 1, 2025 and ending June 30, 2026.

(Dollars in millions)

Three months ended June 30,

2026

2025

Var

%

Comparable cemetery revenue:

Atneed property revenue

$   37.3

$   37.0

$     0.3

0.8 %

Atneed merchandise and service revenue

72.9

74.0

(1.1)

(1.5) %

Total atneed revenue (1)

110.2

111.0

(0.8)

(0.7) %

Recognized preneed property revenue

225.2

220.4

4.8

2.2 %

Recognized preneed merchandise and service revenue

116.2

105.8

10.4

9.8 %

Total recognized preneed revenue (2)

341.4

326.2

15.2

4.7 %

   Core revenue (3)

451.6

437.2

14.4

3.3 %

Other revenue (4)

45.3

36.9

8.4

22.8 %

Total comparable revenue

$  496.9

$  474.1

$   22.8

4.8 %

Comparable gross profit

$  162.2

$  155.5

$     6.7

4.3 %

Comparable gross profit percentage

32.6 %

32.8 %

(0.2) %

Comparable cemetery preneed and atneed sales production:

Property

$  288.5

$  271.2

$   17.3

6.4 %

Merchandise and services

225.3

210.9

14.4

6.8 %

Discounts and other

(5.4)

(3.7)

(1.7)

(45.9) %

Preneed and atneed sales production

$  508.4

$  478.4

$   30.0

6.3 %

Preneed sales production

$  399.5

$  369.8

$   29.7

8.0 %

 Recognition rate (5)

88.8 %

91.4 %

(1)

Atneed revenue represents property, merchandise, and services sold and delivered or performed once death has occurred.

(2)

Recognized preneed revenue represents property, merchandise, and services sold on a preneed contract, which were delivered or performed as well as the related merchandise and service trust fund income.

(3)

Core revenue represents the sum of property, merchandise, and services that have been delivered or performed as well as the related merchandise and service trust fund income.

(4)

Other revenue is primarily related to endowment care trust fund income, royalty income, and interest and finance charges earned from customer receivables on preneed installment contracts.

(5)

Represents the ratio of current period core revenue stated as a percentage of current period preneed and atneed sales production.

Total comparable cemetery revenue increased $22.8 million, or 4.8%, in the second quarter of 2026 compared to the second quarter of 2025. The increase was due to higher core revenue of $14.4 million and higher other revenue of $8.4 million. The core revenue increase of $14.4 million was primarily due to a $15.2 million, or 4.7%, increase in total recognized preneed revenue, of which $4.8 million resulted from higher property revenue and $10.4 million from higher merchandise and service revenue. Merchandise and service revenue also reflects the positive impacts from increased trust fund income. Total recognized preneed revenue benefited from growth in comparable cemetery preneed sales production of $29.7 million, or 8.0%, a significant portion of which will benefit us in the future. Other revenue was $8.4 million higher, or 22.8%, compared to the prior-year quarter primarily from an increase in endowment care trust fund income based on market performance and higher total return distributions. Comparable cemetery gross profit increased $6.7 million to $162.2 million. The gross profit percentage decreased slightly from 32.8% to 32.6%. Gross profit was impacted by higher selling compensation, reflecting strong preneed sales production growth of 8.0%. While this strong production growth puts temporary pressure on cemetery gross margins, it grows our backlog with higher-margin deferred property sales which will benefit us in future periods. Comparable preneed cemetery sales production increased $29.7 million, or 8.0%, and was supported by an increase in the number of contracts sold and a higher sales average as well as an increase in large sales. Other Financial Results

Corporate general and administrative expenses were $41.8 million in the second quarter of 2026, compared to $49.5 million in the prior year. The prior year included a $6.4 million charge related to the settlement of certain legal matters. The remaining decrease is partially due to lower auto and general liability claims in the current year. Interest expense was $64.7 million in the second quarter of 2026 compared to $64.1 million in the prior year. The average balances on our floating-rate debt increased approximately $189.0 million, partially offset by lower average floating rates decreasing from 6.8% to 5.8%, resulting in the net $0.6 million increase in interest expense. The GAAP effective income tax rate for the second quarter of 2026 was 25.1%, down from 25.2% in the prior-year quarter. On an adjusted basis, the effective tax rate was 25.2%, down from 25.4% in the prior-year quarter. The lower effective tax rate in the current period was primarily due to non-taxable gains on the cash surrender value of certain life insurance policies. Cash Flow and Capital Spending

(Dollars in millions)

Three months ended

June 30,

Six months ended

June 30,

2026

2025

2026

2025

Net cash provided by operating activities

$       238.7

$       166.5

$       572.4

$       477.6

Legal settlement payments

0.1

0.5

0.3

0.7

Restructuring charge payments

—

1.3

0.6

5.9

Net cash provided by operating activities excluding special
items

$       238.8

$       168.3

$       573.3

$       484.2

Cash taxes included in net cash provided by operating
activities excluding special items

$         30.0

$         94.3

$         34.4

$         99.2

Net cash provided by operating activities excluding special items grew $70.5 million to $238.8 million in the second quarter of 2026 compared to $168.3 million in the second quarter of 2025. The increase is driven by higher operating income of $7.1 million, and a reduction in cash taxes of $64.3 million, due primarily to credits associated with a renewable energy investment. The related renewable energy investment resulted in a $40.7 million investing cash outflow in the current quarter.  Working capital remained essentially flat overall; however, we saw an improvement of $36.4 million in preneed working capital.  This improvement was primarily driven by collections associated with higher preneed cemetery sales production (for which revenue recognition was deferred) as well as higher collection rates compared to the prior year.  This was offset by $37.3 million in higher accounts payable and other working capital uses due to the timing of an additional payroll cycle within the period compared to the prior year. We expect the favorable preneed cemetery collection rates to continue in the back half of 2026, resulting in our increasing cash flow guidance.

A summary of our capital expenditures is set forth below:

(Dollars in millions)

Three months ended

June 30,

Six months ended

June 30,

2026

2025

2026

2025

Capital improvements at existing field locations

$         29.6

$         29.1

$         49.6

$         49.8

Development of cemetery property

44.5

34.7

85.4

76.0

Digital investments and corporate

6.0

5.1

11.6

9.9

Total maintenance, cemetery development, and other capital
expenditures (Maintenance capital expenditures)

$         80.1

$         68.9

$       146.6

$       135.7

Growth capital expenditures/construction of new funeral
service locations

15.6

14.1

29.0

25.5

Total capital expenditures

$         95.7

$         83.0

$       175.6

$       161.2

Total capital expenditures increased $12.7 million in the current quarter, primarily due to the timing of spend on the development of high-returning cemetery property during the quarter.

Trust Fund Returns

Total trust fund returns include realized and unrealized gains and losses and dividends and are shown gross without netting of certain fees. A summary of our consolidated trust fund returns as of June 30, 2026 is set forth below:

Three Months

Six Months

Preneed funeral

8.0 %

7.1 %

Preneed cemetery

7.8 %

7.1 %

Cemetery perpetual care

7.4 %

6.8 %

Combined trust funds

7.7 %

7.0 %

Non-GAAP Financial Measures

Earnings excluding special items, diluted earnings per share excluding special items, and net cash provided by operating activities excluding special items shown above are non-GAAP financial measures. We believe these non-GAAP financial measures provide a consistent basis for comparison between quarters and years, and better reflect the performance of our core operations by adjusting for the items listed below. We also believe these measures help facilitate comparisons to our competitors' operating results.

Set forth below is a reconciliation of our reported net income attributable to common stockholders to earnings excluding special items and our GAAP diluted earnings per share to diluted earnings per share excluding special items. See "Cash Flow and Capital Spending" in this press release for a reconciliation of net cash provided by operating activities to net cash provided by operating activities excluding special items. We do not intend for this information to be considered in isolation or as a substitute for other measures of performance prepared in accordance with GAAP.

(Dollars in millions, except diluted EPS)

Three months ended June 30,

2026

2025

Net

Income

Diluted

EPS

Net

Income

Diluted

EPS

Net income attributable to common stockholders, as reported

$      124.8

$       0.90

$      122.9

$       0.86

Pre-tax reconciling items:

Losses (gains) on divestitures and impairment charges, net

0.1

—

(4.1)

(0.03)

Legal settlement

—

—

6.4

0.04

Restructuring charge

—

—

1.6

0.01

Tax reconciling items:

Tax effect from significant items

—

—

(0.9)

—

Change in non-recurring tax items

—

—

(0.4)

—

Earnings excluding special items and diluted earnings per share
excluding special items

$      124.9

$       0.90

$      125.5

$       0.88

Diluted weighted average shares outstanding

138.3

143.0

(Dollars in millions, except diluted EPS)

Six months ended June 30,

2026

2025

Net

Income

Diluted

EPS

Net

Income

Diluted

EPS

Net income attributable to common stockholders, as reported

$      260.6

$       1.87

$      265.7

$       1.84

Pre-tax reconciling items:

Gains on divestitures and impairment charges, net

(1.1)

(0.01)

(9.0)

(0.06)

Legal settlement

—

—

6.4

0.04

Restructuring charge

—

—

1.6

0.01

Tax reconciling items:

Tax effect from significant items

0.2

0.01

0.4

0.01

Change in non-recurring tax items

0.4

—

—

—

Earnings excluding special items and diluted earnings per share
excluding special items

$      260.1

$       1.87

$      265.1

$       1.84

Diluted weighted average shares outstanding

139.1

144.1

SOURCE Service Corporation International

Key Takeaways SCI's second-quarter revenues are expected to increase about 1% to $1.1 billion. Preneed cemetery sales, better leads and community outreach likely supported contract growth. Pricing may lift funeral revenues, but soft volumes and higher costs could pressure margins. Service Corporation International (SCI - Free Report) is likely to witness top-line growth when it reports second-quarter 2026 earnings on July 29. The Zacks Consensus Estimate for revenues is pegged at $1.1 billion, indicating an increase of about 1% from the prior-year quarter’s reported figure.

The consensus mark for earnings has remained unchanged over the past 30 days at 87 cents a share, which suggests a decline of 1.1% from the figure reported in the year-ago period. SCI has a trailing four-quarter surprise of 1.7%, on average.

Factors Likely to Influence SCI’s Upcoming ResultsSCI’s cemetery performance is likely to have benefited from sustained preneed sales momentum. Investments in salesforce retention and hiring, improved lead quality, expanded seminars and community-based outreach are likely to have continued to support contract velocity and customer reach beyond funeral-home-generated leads.

Funeral revenues are anticipated to have benefited from disciplined pricing and favorable average revenue per service. Management previously stated that average revenue per service was expected to continue benefiting from older preneed contracts maturing, with accumulated trust earnings and newer, higher-value contracts entering the backlog.

However, funeral service volumes are likely to have remained a key headwind. Management indicated that April volumes were still down, though the decline was less severe than in the first quarter, and expected improvement only gradually through the quarter. The company’s high fixed-cost structure may also have limited margin expansion if funeral volumes remained soft. Higher selling compensation tied to preneed production and elevated cemetery maintenance costs could have added to margin pressure.

Earnings Whispers for SCIOur proven model doesn’t conclusively predict an earnings beat for SCI this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here.

 SCI currently carries a Zacks Rank #3 and has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Stocks With the Favorable CombinationHere are some companies worth considering, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.

Archer-Daniels-Midland Company (ADM - Free Report) currently has an Earnings ESP of +11.52% and a Zacks Rank of 2. The consensus estimate for ADM’s quarterly revenues is pinned at $22.4 billion, which calls for 5.7% growth from the figure reported in the prior-year quarter. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Archer-Daniels’ upcoming quarter’s EPS is pegged at $1.27, which implies a 36.6% rise year over year. ADM delivered a trailing four-quarter earnings surprise of 5.4%, on average.

Kimberly-Clark Corporation (KMB - Free Report) currently has an Earnings ESP of +1.43% and a Zacks Rank of 3. The Zacks Consensus Estimate for Kimberly-Clark’s upcoming quarterly revenues is pegged at $4.2 billion. The figure indicates a 1.7% increase from the prior-year quarter.

The Zacks Consensus Estimate for Kimberly-Clark’s quarterly earnings per share is pegged at $2.00, calling for a 4.2% gain from the year-ago period figure. KMB delivered a trailing four-quarter earnings surprise of 19.1%, on average.

Monster Beverage Corporation (MNST - Free Report) currently has an Earnings ESP of +2.61% and a Zacks Rank of 3. The consensus estimate for Monster Beverage’s quarterly revenues is pinned at $2.4 billion, which suggests 14.5% growth from the figure reported in the prior-year quarter.

The Zacks Consensus Estimate for the upcoming quarter’s EPS is pegged at 59 cents, which calls for a 13.5% jump year over year. MNST delivered a trailing four-quarter earnings surprise of 9.6%, on average.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to launch FDA Registration-Enabling Phase 3 Confirmatory Study to bring Multikine to Market for newly diagnosed head and neck cancer.

U.S. Confirmatory Registration Study expected to begin Summer 2026

Multikine achieved a 73% five-year survival rate versus 45% for standard of care alone in the target patient population and improved quality of life

Saudi partnership includes a 50%/50% net revenue share and supports potential patient access in one of the Middle East's largest oncology markets

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today highlighted its dual-track strategy to bring Multikine® (Leukocyte Interleukin, Injection)* to patients with newly diagnosed locally advanced head and neck cancer through parallel regulatory initiatives in the U.S. and Saudi Arabia.

“Following extensive clinical development and close engagement with regulators, we are excited to begin our final Confirmatory Registration Study, aiming to extend lives and improve the quality of life for head and neck cancer patients,” said Geert Kersten

Share The Company plans to commence its Confirmatory Registration Study of Multikine this summer while simultaneously advancing regulatory and commercialization activities in Saudi Arabia through its strategic partnership with Saudi Amarox.

“Following extensive clinical development and close engagement with regulators, we are excited to begin our final Confirmatory Registration Study, aiming to extend lives and improve the quality of life for head and neck cancer patients,” said Geert Kersten, Chief Executive Officer of CEL-SCI. “We are also looking forward to participating in next week's signing ceremony at BIO with Amarox, our Saudi partner, as we advance a second pathway to bring Multikine to patients.”

U.S. Registration Pathway

CEL-SCI's Confirmatory Registration Study will enroll 212 newly diagnosed, previously untreated, locally advanced resectable head and neck cancer patients with low PD-L1 tumor expression and no lymph node involvement—the patient population that demonstrated the greatest benefit in the Company's completed Phase 3 study.

In that study, patients treated with Multikine before surgery and standard of care therapy achieved a 73% five-year overall survival rate compared to 45% for patients receiving standard of care alone. The confirmatory study is designed to show, among other things, significant improvement in overall survival and support potential registration of Multikine in the United States.

Saudi Market Entry Pathway

CEL-SCI has a strategic partnership with Amarox to support regulatory approval, commercialization and distribution of Multikine in Saudi Arabia. Under the agreement, Amarox is leading local regulatory activities and will be the exclusive distributor of Multikine in the Kingdom upon approval.

The partnership provides a 50%/50% revenue share for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation. Amarox is ranked #1 for Saudi-FDA (SFDA) applications for critical and unavailable medicine for 3 consecutive years. CEL-SCI retains ownership of all Multikine intellectual property, manufacturing know-how and global rights. The agreement also includes the option for Amarox to distribute Multikine throughout the Gulf Cooperation Council (GCC) countries including Bahrain, Kuwait, Oman, Qatar, and the United Arab Emirates.

CEL-SCI and Amarox will conduct a formal signing ceremony during the BIO International Convention in San Diego on June 22, 2026 to highlight their collaboration and commitment to advancing Multikine in the region.

Addressing a Significant Unmet Need

Head and neck cancer is the 6th most common cancer, with approximately 900,000 newly diagnosed cases per year globally. The newly diagnosed stage 3 and 4 patients with this cancer represent a severe unmet need. The target population of the U.S. Confirmatory Registration Study represents approximately 100,000 newly diagnosed head and neck cancer patients annually. Based on CEL-SCI’s completed Phase 3 study of 928 patients, approximately 70% of head and neck cancer patients are estimated to have low or zero PD-L1 tumor expression, a population for whom currently available checkpoint inhibitors may offer only limited benefit with no definitive overall survival benefit.

About Multikine

Multikine is a novel cancer immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated locally advanced head and neck cancer. Its goal is to activate a person’s immune system to fight cancer before the ravages of surgery, radiation and chemotherapy have weakened the immune system. In the world’s largest head and neck cancer Phase 3 study, Multikine increased the 5-year survival rate of the target patient population to 73% vs 45% in patients treated with standard of care alone and halved the risk of death from 55% to 27%.

About CEL-SCI Corporation

CEL-SCI believes that boosting a patient’s immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.

The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, inability to finalize a partnering agreement and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2025. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 2,500,000 shares of common stock at an offering price of $1.00 per share. Total gross proceeds from the offering, before deducting the placement agent’s fees and offering expenses, are expected to be $2.5 million. The offering is expected to close on June 16, 2026, subject to satisfaction of customary closing conditions.

The Company intends to use the proceeds for the continued development of Multikine*, general corporate purposes, and working capital.

ThinkEquity is acting as the sole placement agent for the offering.

The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-288515), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 3, 2025, and declared effective on August 12, 2025. The offering will be made only by means of a written prospectus. A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CEL-SCI Corporation

CEL-SCI believes that boosting a patient’s immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.

The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2025. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.

For the quarter ended March 2026, Service Corp. (SCI - Free Report) reported revenue of $1.1 billion, up 2.1% over the same period last year. EPS came in at $0.97, compared to $0.96 in the year-ago quarter.

The reported revenue represents a surprise of +0.82% over the Zacks Consensus Estimate of $1.09 billion. With the consensus EPS estimate being $1.00, the EPS surprise was -3.24%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Service Corp. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Total comparable funeral average revenue per service: $5,947.00 compared to the $5,920.22 average estimate based on two analysts.Funeral services performed: 93,686 compared to the 94,699 average estimate based on two analysts.Revenue- Funeral: $630.6 million compared to the $642.43 million average estimate based on three analysts. The reported number represents a change of -1.4% year over year.Revenue- Cemetery: $465.9 million compared to the $445.12 million average estimate based on three analysts. The reported number represents a change of +7.2% year over year.Revenue- Cemetery- Core: $425.1 million versus the two-analyst average estimate of $407.71 million. The reported number represents a year-over-year change of +6.4%.Revenues - Cemetery - Total recognized preneed revenue: $315.9 million versus $294.28 million estimated by two analysts on average.Revenue- Cemetery- Core- Atneed: $109.2 million versus $113.42 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.8% change.Revenue- Funeral- Core general agency and other: $54 million versus the two-analyst average estimate of $54.65 million. The reported number represents a year-over-year change of -1.5%.Revenue- Funeral- Non-funeral home preneed sales: $22.1 million versus $23.53 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -0.5% change.Revenue- Cemetery- Other: $40.8 million compared to the $36.79 million average estimate based on two analysts. The reported number represents a change of +15.9% year over year.Gross profit- Funeral: $134 million versus the three-analyst average estimate of $150.86 million.Gross profit- Cemetery: $152.5 million versus $140.51 million estimated by three analysts on average.View all Key Company Metrics for Service Corp. here>>>

Shares of Service Corp. have returned +4.7% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Service Corporation International (SCI) Q1 2026 Earnings Call Transcript

, /PRNewswire/ -- Service Corporation International (NYSE: SCI), the largest provider of deathcare products and services in North America, today announced that its Board of Directors has approved an increase in its quarterly cash dividend to thirty-six cents per share of common stock.  This quarterly cash dividend declared today represents a 6% increase from the previously declared quarterly dividend of thirty-four cents per share of common stock per quarter.  The quarterly cash dividend announced today is payable on June 30, 2026 to shareholders of record at the close of business on June 15, 2026.  While the Company intends to pay regular quarterly cash dividends for the foreseeable future, all subsequent dividends, and the establishment of record and payment dates, are subject to final determination by the Board of Directors each quarter after its review of the Company's financial performance.

Cautionary Statement on Forward-Looking Statements

The statements in this press release that are not historical facts are forward-looking statements.  These forward-looking statements have been made in reliance on the "safe harbor" protections provided under the Private Securities Litigation Reform Act of 1995.  These statements may be accompanied by words such as "believe," "estimate," "project," "expect," "anticipate," or "predict," that convey the uncertainty of future events or outcomes.  These statements are based on assumptions that we believe are reasonable; however, many important factors could cause our actual results in the future to differ materially from the forward-looking statements made herein and in any other documents or oral presentations made by, or on behalf of us.  There can be no assurance that future dividends will be declared.  The actual declaration of future dividends, and the establishment of record and payment dates, is subject to final determination by our Board of Directors each quarter after its review of our financial performance.  Important factors which could cause actual results to differ materially from those in forward-looking statements include, among others, restrictions on the payment of dividends under existing or future credit agreements or other financing arrangements; changes in tax laws relating to corporate dividends; a determination by the Board of Directors that the declaration of a dividend is not in the best interests of the Company and its shareholders; an increase in our cash needs or a decrease in available cash; or a deterioration in our financial condition or results.  For further information on these and other risks and uncertainties, see our Securities and Exchange Commission filings, including our 2025 Annual Report on Form 10-K.  Copies of this document as well as other SEC filings can be obtained from our website at http://www.sci-corp.com.  We assume no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by us, whether as a result of new information, future events or otherwise.

About Service Corporation International

Service Corporation International (NYSE: SCI), headquartered in Houston, Texas, is North America's leading provider of funeral, cemetery and cremation services, as well as final-arrangement planning in advance, serving approximately 700,000 families each year.  Our diversified portfolio of brands provides families and individuals a full range of choices to meet their needs, from simple cremations to full life celebrations and personalized remembrances.  Our Dignity Memorial® brand is the name families turn to for professionalism, compassion, and attention to detail that is second to none.  At March 31, 2026, we owned and operated 1,487 funeral service locations and 503 cemeteries (of which 314 are combination locations) in 44 states, eight Canadian provinces, the District of Columbia, and Puerto Rico.  For more information about Service Corporation International, please visit our website at www.sci-corp.com.  For more information about Dignity Memorial®, please visit www.dignitymemorial.com.

For additional information contact:  [email protected] 

Investors:

Trey Bocage – Assistant Vice President / Investor Relations

(713) 525-3454

Andrea Low – Director / Investor Relations

(713) 525-2811

Media:

Jay Andrew – Assistant Vice President / Corporate Communications

(713) 525-3468

SOURCE Service Corporation International

Image: Bigstock

Read MoreHide Full Article

Key Takeaways SCI increased the quarterly dividend to 36 cents per share, reinforcing its steady shareholder return focus.SCI returned $190M in Q1 2026, including $143M buybacks of nearly 2M stock at $80 per share.SCI's preneed cemetery sales production rose 10% YoY; it invested $108M and spent $24M on acquisitions. Service Corporation International (SCI - Free Report) , the largest provider of deathcare products and services in North America, continues to reinforce its commitment to consistent shareholder returns through disciplined capital allocation and stable cash flow generation.

Service Corp announced a quarterly cash dividend increase to 36 cents per share from the previously declared 34 cents, marking a 6% hike. The dividend will be payable on June 30, 2026, to its shareholders of record at the close of business on June 15. The latest dividend increase reflects management’s confidence in the company’s resilient business model and long-term financial strength.

SCI has consistently prioritized returning capital to its shareholders through regular dividend increases, supported by dependable demand trends in funeral, cemetery and cremation services. The company’s broad geographic footprint and diversified service offerings continue to provide stable recurring revenues and strong cash-generation capabilities.

In first-quarter 2026, Service Corp returned $190 million in capital to its shareholders, comprising $143 million in share repurchases and $47 million in dividend payments. The company bought back nearly 2 million shares during the quarter at an average price of roughly $80 per share, bringing its outstanding share count to a little more than 130 million as of the end of March.

Management noted that while it intends to continue paying regular quarterly dividends, future declarations will remain subject to board approval following a review of financial performance and liquidity conditions. The company also highlighted potential risks, including financing restrictions, tax law changes and shifts in cash requirements, which could affect future dividend decisions.

What More Should Investors Know About SCI?Headquartered in Houston, TX, SCI currently operates 1,487 funeral service locations and 503 cemeteries across North America under several recognized brands, including Dignity Memorial. Serving nearly 700,000 families annually, the company remains well positioned to drive long-term growth while maintaining a strong shareholder-friendly capital return strategy.

Service Corp continues to benefit from strong momentum in its preneed cemetery business, supported by healthy sales execution and expanding community outreach initiatives. In first-quarter 2026, preneed cemetery sales production increased 10% year over year, driven by robust large sales activity and improving sales velocity. Management highlighted growing success from seminar-based marketing efforts, expansion of community sales teams and improved lead generation strategies, which are helping SCI reach customers beyond traditional funeral-home channels.

The company is also strengthening its long-term growth platform through strategic investments and acquisitions. During the quarter, SCI invested $108 million across maintenance projects, cemetery development, digital initiatives and new funeral-home construction. Additionally, the company spent $24 million on acquisitions across multiple states, while management indicated continued optimism regarding its acquisition pipeline for 2026.

In the past six months, this Zacks Rank #4 (Sell) company has lost 2.1% against the industry’s 1.1% growth.

SCI Stock's Price Performance
Image Source: Zacks Investment Research

Stocks to ConsiderSmithfield Foods, Inc. (SFD - Free Report) produces various packaged meats and fresh pork products in the United States and internationally. It carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for Smithfield Foods’ current financial-year sales and earnings indicates growth of 1.3% and 7.5%, respectively, from the prior-year reported levels. SFD delivered a trailing four-quarter earnings surprise of 12%, on average.

Tyson Foods, Inc. (TSN - Free Report) operates as a food company through the Beef, Pork, Chicken and Prepared Foods segments. TSN currently carries a Zacks Rank #2.

The Zacks Consensus Estimate for Tyson Foods’ current fiscal-year sales calls for growth of 3.7%, while the same for earnings indicates a decline of 0.2% from the year-ago figures. TSN delivered a trailing four-quarter earnings surprise of 18.1%, on average.

Post Holdings (POST - Free Report) operates as a consumer-packaged goods holding company. At present, POST carries a Zacks Rank of 2.

The consensus estimate for Post Holdings’ current fiscal-year sales and earnings implies growth of 2.7% and 0.1%, respectively, from the year-ago figures. POST delivered a trailing four-quarter earnings surprise of 19.6%, on average.

Zacks' 7 Best Strong Buy Stocks (New Research Report) Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.

Click Here, It's Really Free

Published in consumer-staples

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation Announces Pricing of Public Offering.

Service Corporation International (SCI) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Service Corporation International remains a stable, cash-generating leader in the fragmented death care industry, operating 1,487 funeral homes and 503 cemeteries. I reaffirm SCI as a "Buy" due to attractive valuation, consistent shareholder returns, and resilience amid challenging economic conditions. SCI's 2026 projections show rising revenue, net profits, and operating cash flow, with net leverage and capital returns well managed.

Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company") congratulates its Founder and Chief Technology Officer, Professor Jason Hein, on receiving the 2026 SCI Canada LeSueur Memorial Award from the Society of Chemical Industry ("SCI").

Figure 1. The 2026 LeSeueur Memorial Award Presented to Professor Jason Hein

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8923/300261_328197891408ab84_001full.jpg

Administered by the Society of Chemical Industry, a professional body founded in London in 1881 and incorporated by Royal Charter in 1907, the LeSueur Memorial Award was established in 1955 in honour of Ernest A. LeSueur, a pioneer in Canadian chemical engineering. The award is presented for technical excellence, in either a university or industrial setting in Canada, with a contribution to Canadian industry through chemical creativity and innovation. Past recipients include distinguished leaders from institutions such as the University of British Columbia, the University of Toronto, McMaster University, and the University of Waterloo, as well as senior innovators from organizations including DuPont, Gilead, and Syncrude. The award is presented annually at the SCI Canada Awards Dinner and is among the most respected honours in the Canadian chemical sciences community. Professor Hein, who also serves as Professor of Chemistry at the University of British Columbia, is recognized for his work at the intersection of physical organic chemistry, reaction mechanism, automation, and deployable technology.

The LeSueur Memorial Award follows Professor Hein's receipt of the 2025 R.U. Lemieux Award from the Chemical Institute of Canada, further reflecting the growing recognition of his contributions to chemical research and pharmaceutical manufacturing innovation.

Henry Dubina, Telescope's CEO, commented, "Jason's recognition with the LeSueur Memorial Award is a testament to the caliber of scientific leadership at the heart of Telescope. His ability to bridge fundamental chemistry, AI, and automation is what makes our Self-Driving Lab technology possible. We are proud to have a CTO whose vision continues to earn recognition at this level."

About Telescope Innovations

Telescope Innovations Corp. is a developer of reaction sampling technology, intelligent automation and advanced chemical manufacturing technologies. The Company builds and deploys enabling technologies including reaction sampling systems for real-time analysis, flexible robotic platforms, and artificial intelligence software that improves experimental throughput, efficiency, and data quality. The Company's "Self-Driving Labs" are fully autonomous, physical AI platforms that plan, execute, and analyze experiments far more efficiently than traditional manual approaches. Bio-pharmaceutical, high value specialty chemical, and advanced materials companies utilize Telescope's products and services to accelerate the development and optimization of chemical processes, thereby cutting down time and costs from lab to market. For more information, please visit www.telescopeinnovations.com.

On behalf of the Board,

Telescope Innovations Corp.

Forward-Looking Information

This press release may contain forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Telescope Innovations to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. These statements relate to future events or future performance, reflect management's current expectations and are based on information currently available to management. A number of factors could cause actual events, performance, or results to differ materially from what is projected in the forward-looking statements, including without limitation: technological risks and uncertainties; market acceptance of Telescope's technology; the Company's ability to retain key personnel; general economic conditions; and other risks detailed in the Company's public filings. The Company does not undertake to update any forward-looking information except in accordance with applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300261

Source: Telescope Innovations Corp.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI and Saudi Amarox to conduct signing ceremony at BIO 2026 for Strategic Agreement to advance commercialization and distribution of Multikine.